Pretreatment patient characteristics
Variable . | Total cohort, N = 664 . | Younger patients (<60 y), N = 376 . | Older patients (≥60 y), N = 288 . |
---|---|---|---|
Age (y) | |||
Median | 57 | 45 | 67 |
Range | 18-86 | 18-59 | 60-68 |
Female gender, n (%) | 330 (50) | 203 (54) | 127 (44) |
De novo AML | 570 (86) | 335 (89) | 235 (82) |
Secondary AML | 59 (9) | 22 (6) | 37 (13) |
Therapy-related AML | 35 (5) | 19 (5) | 16 (6) |
ECOG performance status, n (%) | |||
0 | 172 (27) | 111 (30) | 61 (22) |
1 | 313 (48) | 175 (47) | 138 (49) |
2 | 125 (19) | 59 (16) | 66 (24) |
3 | 33 (5) | 20 (5) | 13 (5) |
4 | 6 (1) | 4 (1) | 2 (1) |
WBC count, ×109/L | |||
Median | 23.4 | 25.7 | 20.9 |
Range | 0.1-666 | 0.1-486 | 0.5-666 |
Hemoglobin, g/dL | |||
Median | 9.0 | 9.0 | 9.0 |
Range | 3.5-16.0 | 3.5-15.6 | 3.8-16 |
Platelet count, ×109/L | |||
Median | 53 | 52 | 55 |
Range | 1-1760 | 1-1760 | 1-471 |
Bone marrow blasts, % | |||
Median | 80 | 80 | 80 |
Range | 6-100 | 6-100 | 9-100 |
FAB category, n | |||
M0 | 35 | 16 | 19 |
M1 | 157 | 80 | 77 |
M2 | 178 | 93 | 85 |
M4 | 163 | 107 | 56 |
M5 | 83 | 51 | 32 |
M6 | 19 | 11 | 8 |
M7 | 3 | 3 | 0 |
MRC cytogenetic risk category | |||
Favorable | 65 (10) | 50 (14) | 15 (5) |
Intermediate | 452 (70) | 254 (69) | 198 (71) |
Adverse | 129 (20) | 65 (18) | 64 (23) |
Modified ELN classification* | |||
Favorable | 189 (29) | 128 (35) | 61 (22) |
Intermediate-I | 205 (32) | 107 (29) | 98 (35) |
Intermediate-II | 119 (18) | 62 (17) | 57 (21) |
Adverse | 133 (21) | 72 (20) | 61 (22) |
NPM1-mutated, n (%) | 221 (33) | 129 (34) | 92 (32) |
FLT3-ITD present, n (%) | 197 (30) | 119 (32) | 78 (27) |
CEBPA, n (%) | |||
Single mutation | 25 (4) | 13 (3) | 12 (4) |
Double mutation | 27 (4) | 22 (6) | 5 (2) |
DNMT3A-mutated, n (%) | 209 (31) | 108 (29) | 101 (35) |
RUNX1-mutated, no. (%) | 102 (15) | 35 (9) | 67 (23) |
TP53 mutated, n (%) | 63 (9) | 23 (6) | 40 (14) |
Variable . | Total cohort, N = 664 . | Younger patients (<60 y), N = 376 . | Older patients (≥60 y), N = 288 . |
---|---|---|---|
Age (y) | |||
Median | 57 | 45 | 67 |
Range | 18-86 | 18-59 | 60-68 |
Female gender, n (%) | 330 (50) | 203 (54) | 127 (44) |
De novo AML | 570 (86) | 335 (89) | 235 (82) |
Secondary AML | 59 (9) | 22 (6) | 37 (13) |
Therapy-related AML | 35 (5) | 19 (5) | 16 (6) |
ECOG performance status, n (%) | |||
0 | 172 (27) | 111 (30) | 61 (22) |
1 | 313 (48) | 175 (47) | 138 (49) |
2 | 125 (19) | 59 (16) | 66 (24) |
3 | 33 (5) | 20 (5) | 13 (5) |
4 | 6 (1) | 4 (1) | 2 (1) |
WBC count, ×109/L | |||
Median | 23.4 | 25.7 | 20.9 |
Range | 0.1-666 | 0.1-486 | 0.5-666 |
Hemoglobin, g/dL | |||
Median | 9.0 | 9.0 | 9.0 |
Range | 3.5-16.0 | 3.5-15.6 | 3.8-16 |
Platelet count, ×109/L | |||
Median | 53 | 52 | 55 |
Range | 1-1760 | 1-1760 | 1-471 |
Bone marrow blasts, % | |||
Median | 80 | 80 | 80 |
Range | 6-100 | 6-100 | 9-100 |
FAB category, n | |||
M0 | 35 | 16 | 19 |
M1 | 157 | 80 | 77 |
M2 | 178 | 93 | 85 |
M4 | 163 | 107 | 56 |
M5 | 83 | 51 | 32 |
M6 | 19 | 11 | 8 |
M7 | 3 | 3 | 0 |
MRC cytogenetic risk category | |||
Favorable | 65 (10) | 50 (14) | 15 (5) |
Intermediate | 452 (70) | 254 (69) | 198 (71) |
Adverse | 129 (20) | 65 (18) | 64 (23) |
Modified ELN classification* | |||
Favorable | 189 (29) | 128 (35) | 61 (22) |
Intermediate-I | 205 (32) | 107 (29) | 98 (35) |
Intermediate-II | 119 (18) | 62 (17) | 57 (21) |
Adverse | 133 (21) | 72 (20) | 61 (22) |
NPM1-mutated, n (%) | 221 (33) | 129 (34) | 92 (32) |
FLT3-ITD present, n (%) | 197 (30) | 119 (32) | 78 (27) |
CEBPA, n (%) | |||
Single mutation | 25 (4) | 13 (3) | 12 (4) |
Double mutation | 27 (4) | 22 (6) | 5 (2) |
DNMT3A-mutated, n (%) | 209 (31) | 108 (29) | 101 (35) |
RUNX1-mutated, no. (%) | 102 (15) | 35 (9) | 67 (23) |
TP53 mutated, n (%) | 63 (9) | 23 (6) | 40 (14) |
ECOG, Eastern Cooperative Oncology Group; ELN, European LeukemiaNet; FAB, French-American-British classification; ITD, internal tandem duplication; MRC, British Medical Research Council.
Modified ELN classification designates the ELN reporting system for genetic alterations14; however only patients with double, and not those with single, CEBPA mutations were classified as “favorable.”